Hjem › Kronisk lymfatisk leukæmi › Oregon
Kronisk lymfatisk leukæmi kliniske forsøg i Oregon
16 studier for Kronisk lymfatisk leukæmi søger deltagere på steder i Oregon.
Byer i Oregon
Officiel studietekst (engelsk)
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- og 1 flere
RekruttererFase 3
Alder 65 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- og 7 flere
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 40 til 75 · Alle køn · Opdateret 2. okt. 2026 · NCT05334069Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Saint Charles Health System, Bend
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- og 1 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT04269902A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Oncology Associates of Oregon Willamette Valley Cancer Center, Eugene
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT06943872A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Oncology Associates of Oregon Willamette Valley Cancer Center, Eugene
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT07277231A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- Oncology Associates of Oregon Willamette Valley Cancer Center, Eugene
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT06846671A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- Oregon Health and Science University ( Site 5425), Portland
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 24. sep. 2026 · NCT05947851Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
- OHSU Knight Cancer Institute, Portland
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT06784167A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Research Site, Portland
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 8. sep. 2026 · NCT06564038Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- Oncology Associates of Oregon, Eugene
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. aug. 2026 · NCT07520006Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Oregon Health & Science University, Portland
RekruttererFase 1/2
Alder 13 til 90 · Alle køn · Opdateret 6. aug. 2026 · NCT06533579A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Williamette Valley Cancer Institute & Research Center, Eugene
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 19. maj 2026 · NCT06588478A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Willamette Valley Cancer Institute and Research Center /ID# 266326, Eugene
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 9. apr. 2026 · NCT06428019Study of SGR-1505 in Mature B-Cell Neoplasms
- Oregon Health and Science University - Knight Cancer Institute, Portland
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 13. feb. 2026 · NCT05544019Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
- OHSU Knight Cancer Institute, Portland
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 6. nov. 2025 · NCT05943496A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- Oregon Health & Science University, Portland
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2025 · NCT05780034Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.